Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FUJRW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 80 mg tablets (60-count units) with a ceiling value of $4,169.59. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November 2026. The place of performance is Park Ridge, Illinois, with an ultimate completion date of September 4, 2025.
This delivery order exemplifies DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, particularly for military healthcare facilities. Xtandi is an oncology treatment medication, reflecting the company's consistent portfolio of specialized pharmaceuticals delivered to Department of Defense healthcare sites. As the prime contractor on this award, DMS Pharmaceutical Group leverages its comprehensive IDC to provide branded and generic prescription drugs, biologics, and medical consumables to support the medical supply needs of military health facilities nationwide. The firm fixed-price structure ensures cost predictability for the government while maintaining the company's competitive positioning in federal pharmaceutical procurement markets.
Quick answers
Who was awarded contract SPE2DB25FUJRW?
SPE2DB25FUJRW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FUJRW worth?
The government has obligated $4,170 on SPE2DB25FUJRW.
Is contract SPE2DB25FUJRW an order under another contract?
Yes. SPE2DB25FUJRW is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJRW competed?
The extent of competition for SPE2DB25FUJRW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award